Скачать или смотреть $LLY: Eli Lilly Stock Explodes After Earnings | $LLY Q4 Beat & 2026 Outlook

Eli Lilly vs Competitors: Who’s Winning the GLP-1 Weight Loss War?
Eli Lilly (LLY) is trending sharply higher as investors react to a *blowout Q4 2025 earnings report* and an **upbeat 2026 profit outlook**, reinforcing the company’s status as one of the dominant forces in the fast-growing obesity and diabetes treatment markets.

📊 *Q4 2025 Earnings: Growth Machine in Action*

Lilly delivered another blockbuster quarter, reporting:
**Revenue up 43% YoY to $19.3 billion**, far exceeding expectations
**Non-GAAP EPS of $7.54**, reflecting strong operating leverage and expanding margins
Robust volume-driven growth, primarily from *Mounjaro (diabetes)* and **Zepbound (obesity)**, which continue to see demand outstrip supply in many regions.
Management highlighted continued manufacturing ramp-ups and supply chain investments, signaling confidence that Lilly can better meet global demand heading into 2026. - https://equity4keeps.com/LLY_Stock.htm
Join this channel to get access to perks:
   / @equity4keeps  

Consider Supporting this Channel via PayPal: https://www.paypal.com/donate/?hosted...